HeiLongJiang ZBD Pharmaceutical Co., Ltd.SSE: 603567

Announcement on Obtaining Drug Registration Certificate by the Wholly-owned Subsidiary

· Issued by HeiLongJiang ZBD Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 2 pages · Chinese

Summary by 6ix AI

HeiLongJiang ZBD Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary has obtained a drug registration certificate for a specific antibiotic product. The drug, moxifloxacin hydrochloride tablets, is approved for production and sale in the domestic market, enhancing the company's product offerings in the anti-infection sector. The company has invested significantly in the research and development of this drug, which is expected to improve its competitive position in the market. However, the company cautions that production and sales are subject to regulatory and market uncertainties.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Release

Announcement on Obtaining Drug Registration Certificate by the Wholly-owned Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

HeiLongJiang ZBD Pharmaceutical Co., Ltd. on 6ix

Earlier from HeiLongJiang ZBD Pharmaceutical

Later from HeiLongJiang ZBD Pharmaceutical

All HeiLongJiang ZBD Pharmaceutical news releases